BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-05 pm EDT
254.23 USD   +0.68%
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Evercore ISI Adjusts Price Target on Becton Dickinson and Co. to $265 From $300, Keeps Outperform Rating

07/05/2022 | 09:54am EDT


© MT Newswires 2022
All news about BECTON, DICKINSON AND COMPANY
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/04Becton Dickinson Raises FY22 Guidance
DJ
08/04Becton, Dickinson Reports Higher Fiscal Q3 Results, Raises Full-Year Outlook
MT
08/04BECTON DICKINSON AND : BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS - Form 8-K
PU
08/04BECTON DICKINSON : Fiscal Q3 Earnings Snapshot
AQ
08/04GUIDANCE : (BDX) BD (BECTON DICKINSON AND COMPANY) Forecasts Fiscal Year 2022 EPS Range $1..
MT
08/04Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Reports Q3 Revenue $4.64B
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 822 M - -
Net income 2022 1 866 M - -
Net Debt 2022 13 567 M - -
P/E ratio 2022 37,2x
Yield 2022 1,49%
Capitalization 72 505 M 72 505 M -
EV / Sales 2022 4,57x
EV / Sales 2023 4,36x
Nbr of Employees 75 000
Free-Float 77,5%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 254,23 $
Average target price 274,67 $
Spread / Average Target 8,04%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY3.44%72 505
ABBOTT LABORATORIES-22.37%191 321
MEDTRONIC PLC-9.83%123 942
HOYA CORPORATION-14.17%39 100
DEXCOM, INC.-33.63%34 975
SARTORIUS STEDIM BIOTECH-22.95%34 798